Pancreatic Cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pancreatic Cancer: Overview
Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they start in. Knowing the type of tumor is important because each type acts differently and responds to different treatments. About 93% of pancreatic cancers are exocrine tumors. The most common type of pancreatic cancer is adenocarcinoma. About 7% of pancreatic tumors are neuroendocrine tumors (pancreatic NETs or PNETs), also called islet cell tumors. They often grow slower than exocrine tumors. A pancreatic tumor can only be seen on an imaging study such as a computed tomography (CT) scan, magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Pancreatic cancer treatment depends on the stage of the disease and the patient’s general health.
'Pancreatic Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pancreatic Cancer Emerging Drugs
Further product details are provided in the report..
Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.
Pancreatic Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pancreatic Cancer: Overview
Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they start in. Knowing the type of tumor is important because each type acts differently and responds to different treatments. About 93% of pancreatic cancers are exocrine tumors. The most common type of pancreatic cancer is adenocarcinoma. About 7% of pancreatic tumors are neuroendocrine tumors (pancreatic NETs or PNETs), also called islet cell tumors. They often grow slower than exocrine tumors. A pancreatic tumor can only be seen on an imaging study such as a computed tomography (CT) scan, magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Pancreatic cancer treatment depends on the stage of the disease and the patient’s general health.
'Pancreatic Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic Cancer.
This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pancreatic Cancer Emerging Drugs
- CPI-613 (devimistat): Rafael Pharmaceuticals
- Masitinib: AB Science
- EndoTAG-1: Syncore Biotechnology
- Acalabrutinib: Acerta Pharma
- SM-88 (racemetyrosine): Tyme Technologies
- Pamrevlumab: FibroGen
Further product details are provided in the report..
Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pancreatic Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.
Pancreatic Cancer Report Insights
- Pancreatic Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pancreatic Cancer drugs?
- How many Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Rafael Pharmaceuticals
- AB Science
- Syncore Biotechnology
- Acerta Pharma
- Tyme Technologies
- FibroGen
- Marker Therapeutics
- Bristol-Myers Squibb
- Helix BioPharma
- Golden Biotechnology Corporation
- NOXXON Pharma
- Takara Bio
- ARMO BioSciences
- Rise Biopharmaceuticals
- NanoCarrier
- BeyondBio
- Rexahn Pharmaceuticals, Inc.
- Wuhan Binhui Biotechnology Co., Ltd.
- Everfront Biotech Co., Ltd.
- XBiotech, Inc.
- Jiangsu Hengrui Medicine Co.
- Asclepius Technology Company Group
- Ability Pharmaceuticals
- Lokon Pharma AB
- Immunitor
- Sumitomo Dainippon Pharma Oncology
- Berg, LLC
- BioXcel Therapeutics
- Sunshine Lake Pharma
- 4D Pharma PLC
- CrystalGenomics
- Salspera
- BioNTech SE
- Rgene Corporation
- Pharmexa
- TESARO
- Cend Therapeutics
- AbbVie
- Galera Therapeutics, Inc.
- Genentech
- NGM Biopharmaceuticals, Inc
- Carsgen Therapeutics, Ltd.
- Ascentage Pharma Group Inc.
- Panbela Therapeutics, Inc.
- Sorrento Therapeutics
- Silenseed Ltd
- Takeda Oncology
- Scandion Oncology
- NanOlogy, LLC
- Celldex Therapeutics Inc
- BioLineRx
- BerGenBio ASA
- CPI-613 (devimistat)
- Masitinib
- EndoTAG-1
- Acalabrutinib
- SM-88 (racemetyrosine)
- Pamrevlumab
- Zelenoleucel
- Nivolumab
- L-DOS47
- Antroquinonol
- Olaptesed pegol
- TBI-1401
- Pegilodecakin
- RP72
- NC-6004
- BEY1107
- RX-3117
- OH2 injection
- EF-009
- XB2001
- SHR-1701
- BiCAR-NK
- ABTL0812
- delolimogene mupadenorepvec
- V3-P
- Napabucasin
- BPM31510
- Talabostat Mesylate
- Z650
- SHR 3162
- MRx0518
- CG200745
- Salmonella-IL2
- MVT-5873
- BLEX 404
- GV1001
- Niraparib
- CEND-1
- ABBV-927
- GC4711
- Atezolizumab
- MVT-2163
- NGM120
- CT041
- APG-1387
- SBP-101
- Anti CEA CAR T cell therapy
- siG12D-LODER
- TAK-931
- SCO-101
- NanoPa
- CDX-301
- BL-8040
- BGB324
Introduction
Executive Summary
Pancreatic Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pancreatic Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pancreatic Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pancreatic Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pamrevlumab: FibroGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Acalabrutinib: Acerta Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
RP72: Rise Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Pancreatic Cancer Key Companies
Pancreatic Cancer Key Products
Pancreatic Cancer- Unmet Needs
Pancreatic Cancer- Market Drivers and Barriers
Pancreatic Cancer- Future Perspectives and Conclusion
Pancreatic Cancer Analyst Views
Pancreatic Cancer Key Companies
Appendix
Executive Summary
Pancreatic Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pancreatic Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pancreatic Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pancreatic Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Pamrevlumab: FibroGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Acalabrutinib: Acerta Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
RP72: Rise Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Pancreatic Cancer Key Companies
Pancreatic Cancer Key Products
Pancreatic Cancer- Unmet Needs
Pancreatic Cancer- Market Drivers and Barriers
Pancreatic Cancer- Future Perspectives and Conclusion
Pancreatic Cancer Analyst Views
Pancreatic Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pancreatic Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pancreatic Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pancreatic Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pancreatic Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products